Atezolizumab and Recombinant Human Hyaluronidase for Non-Small Cell Lung Cancer
Study Summary
This trial is testing whether atezolizumab, given at home via telemedicine, is safe and feasible for patients with non-small cell lung cancer.
- Non-Small Cell Lung Cancer
- Stage IIB Lung Cancer
- Stage IVB Lung Cancer
- Stage III Lung Cancer
- Stage IIIB Lung Cancer
- Stage IVA Lung Cancer
- Stage IIIA Lung Cancer
- Stage II Lung Cancer
- Stage IIA Lung Cancer
- Stage IV Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Treatment (atezolizumab and recombinant human hyaluronidase)
1 of 1
Experimental Treatment
37 Total Participants · 1 Treatment Group
Primary Treatment: Atezolizumab and Recombinant Human Hyaluronidase · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Do the benefits of Atezolizumab and Recombinant Human Hyaluronidase outweigh the risks?
"Atezolizumab and Recombinant Human Hyaluronidase's safety has been supported in some ways by data, but not efficacy. Thus, we have given it a score of 2." - Anonymous Online Contributor
Are participants being enrolled in this clinical trial at this time?
"No, the trial has stopped recruiting patients as of their last update on November 12th, 2022 according to information found on clinicaltrials.gov. The study was first posted December 5th, 2020. There are 2098 other trials that are still recruiting patients." - Anonymous Online Contributor